Cancer-related anemia
Standard
Cancer-related anemia : pathogenesis, prevalence and treatment. / Birgegård, Gunnar; Aapro, Matti S; Bokemeyer, Carsten; Dicato, Mario; Drings, Peter; Hornedo, Javier; Krzakowski, Maciej; Ludwig, Heinz; Pecorelli, Sergio; Schmoll, Hans; Schneider, Maurice; Schrijvers, Dirk; Shasha, Daniel; Van Belle, Simon.
In: ONCOLOGY-BASEL, Vol. 68 Suppl 1, 2005, p. 3-11.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cancer-related anemia
T2 - pathogenesis, prevalence and treatment
AU - Birgegård, Gunnar
AU - Aapro, Matti S
AU - Bokemeyer, Carsten
AU - Dicato, Mario
AU - Drings, Peter
AU - Hornedo, Javier
AU - Krzakowski, Maciej
AU - Ludwig, Heinz
AU - Pecorelli, Sergio
AU - Schmoll, Hans
AU - Schneider, Maurice
AU - Schrijvers, Dirk
AU - Shasha, Daniel
AU - Van Belle, Simon
N1 - Copyright 2005 S. Karger AG, Basel
PY - 2005
Y1 - 2005
N2 - Cancer-related anemia is a cytokine-mediated disorder resulting from complex interactions between tumor cells and the immune system. Overexpression of certain inflammatory cytokines results in shortened survival of red blood cells, suppression of erythroid progenitor cells, impaired iron utilization, and inadequate erythropoietin production. Numerous other factors may also contribute to the development of anemia in cancer patients. The European Cancer Anaemia Survey (ECAS) has provided the most current, comprehensive, prospectively collected data on the incidence and prevalence of anemia among cancer patients, as well as important perspectives on anemia treatment and relationship of hemoglobin and performance status. ECAS enrolled over 15,000 treated and untreated patients with various malignancies from cancer centers in 24 European countries and followed them for up to 6 months. The initial analysis of the ECAS data revealed that 39% of the total cancer patient population was anemic (hemoglobin <12.0 g/dl) at enrollment, although the rate varied according to tumor type, disease status, and cancer treatment status. Of the patients who were not anemic at enrollment and started cancer treatment during the survey, those undergoing chemotherapy--either alone or in combination with radiotherapy--had the highest incidence of anemia (63 and 42%, respectively). Low hemoglobin levels correlated with poor performance status and only 40% of patients who were anemic at some time during the survey received treatment for their anemia. These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients' quality of life and may also improve the clinical outcome.
AB - Cancer-related anemia is a cytokine-mediated disorder resulting from complex interactions between tumor cells and the immune system. Overexpression of certain inflammatory cytokines results in shortened survival of red blood cells, suppression of erythroid progenitor cells, impaired iron utilization, and inadequate erythropoietin production. Numerous other factors may also contribute to the development of anemia in cancer patients. The European Cancer Anaemia Survey (ECAS) has provided the most current, comprehensive, prospectively collected data on the incidence and prevalence of anemia among cancer patients, as well as important perspectives on anemia treatment and relationship of hemoglobin and performance status. ECAS enrolled over 15,000 treated and untreated patients with various malignancies from cancer centers in 24 European countries and followed them for up to 6 months. The initial analysis of the ECAS data revealed that 39% of the total cancer patient population was anemic (hemoglobin <12.0 g/dl) at enrollment, although the rate varied according to tumor type, disease status, and cancer treatment status. Of the patients who were not anemic at enrollment and started cancer treatment during the survey, those undergoing chemotherapy--either alone or in combination with radiotherapy--had the highest incidence of anemia (63 and 42%, respectively). Low hemoglobin levels correlated with poor performance status and only 40% of patients who were anemic at some time during the survey received treatment for their anemia. These findings are noteworthy, since a growing body of clinical evidence indicates that the treatment of anemia can significantly improve patients' quality of life and may also improve the clinical outcome.
KW - Anemia, Hypochromic
KW - Chemotherapy, Adjuvant
KW - Erythropoietin
KW - Hematinics
KW - Hemoglobins
KW - Humans
KW - Neoplasms
KW - Prevalence
KW - Prospective Studies
KW - Radiotherapy, Adjuvant
KW - Recombinant Proteins
U2 - 10.1159/000083128
DO - 10.1159/000083128
M3 - SCORING: Journal article
C2 - 15855811
VL - 68 Suppl 1
SP - 3
EP - 11
JO - ONCOLOGY-BASEL
JF - ONCOLOGY-BASEL
SN - 0030-2414
ER -
